PT 141 or bremelanotide is a peptide hormone derived from a natural peptide and is commonly used in treating erectile dysfunction for males as a result of pregnancy. PT 141 is able to control blood flow to both the vagina and the clitoris and increases sexual desires. PT 141 provides PT 141 patients with a safe option when considering treatment options.. Continue reading for information on pto141 and its benefits.
Generic Vyleesi (bremelanotide), also known as PT-141, is a game changer for female sexual dysfunction, specifically Hypoactive Sexual Desire Disorder (HSDD). With FDA approval in June 2019, Vyleesi is a new treatment for premenopausal women whose low sexual desire is not related to medical or psychological conditions, medication side effects or relationship issues. Vyleesi helps to increase libido in premenopausal women, offering a unique mechanism of action through the hormone and central nervous system.
HSDD is a medical condition where a woman has a persistent lack of sexual interest which causes personal distress or difficulties in relationships. It’s estimated that nearly 10% of women may experience HSDD, which affects a woman's sex drive and overall well-being. This is not just low libido but a complex issue that can impact both sexual function and intimacy and a woman’s emotional and relational well being.
Vyleesi is often mistaken as the “female Viagra.” But unlike Viagra which targets the vascular system to enhance sexual performance, Vyleesi acts on the brain’s neural pathways and the nervous system to regulate sexual desire. This is a big difference as it addresses the psychological components of sexual desire and arousal, not just physical arousal.
Generic Vyleesi is different from its predecessor Addyi (flibanserin) in its administration method. As an injectable taken as needed, Vyleesi is more flexible and convenient for planning sexual activity. This allows women to be in control of their sexual health on their own terms, making it a more user friendly option.
Nausea is the most common side effect of Vyleesi. Users may also experience flushing, headaches and reactions at the injection site. Some may experience a temporary increase in blood pressure and changes in blood flow, such as increased blood pressure, and changes in skin or gum pigmentation. Potential users should weigh these side effects against the benefits and discuss with their healthcare provider.
The FDA approval of Vyleesi was based on clinical trials that showed significant improvement in sexual desire and decrease in distress among participants, better than the placebo. These trials provided strong evidence of its effectiveness, making it a well studied treatment for HSDD. Additionally, the trials also showed improvements in sexual satisfaction among participants.
Cost and availability was not disclosed at the time of approval but expected to be available by September 2019. Affordability will be key for potential users. Making Vyleesi available to as many women as possible will be the key to its success and acceptance.
The introduction of generic Vyleesi is a big step towards gender equality in sexual health treatments. For too long male sexual dysfunction has had many pharmaceutical solutions while female sexual health has been ignored. Vyleesi helps to bridge that gap, it’s an important option to treat sexual dysfunction in women.
Peptide Hackers supplies research peptides as part of peptide therapy. PT-141 is for research use only. While Vyleesi is FDA approved for clinical use in women, Peptide Hackers PT-141 is not for human consumption. Researchers can further explore its potential and add to the body of knowledge on female sexual health.
The release of generic Vyleesi opens up more research on female sexual dysfunction. PT-141 is composed of amino acids, which are the building blocks of peptides. Future studies will dig deeper into PT-141’s mechanism of action, long term effects and across different populations. Knowing how this peptide works can lead to new treatments and better outcomes in sex life for women with HSDD.
With Vyleesi on the market, healthcare providers need to be educated on its indications, dosing and side effects to ensure proper patient selection and management. Education will ensure Vyleesi is prescribed correctly and patients get the full health benefits out of this new treatment. Healthcare providers should also be aware of PT-141's potential benefits for treating erectile dysfunction in men.
The approval of generic Vyleesi (PT-141) is a big step in addressing the long ignored female sexual desire disorders. It’s a new treatment option for women with HSDD and is effective in increasing sexual desire. This highlights the importance of sexual health in women’s overall well being. The impact of Vyleesi on women’s lives, sexual function, healthcare and future research will be big and far reaching.
